SK bioscience Co.,Ltd. (KRX:302440)

South Korea flag South Korea · Delayed Price · Currency is KRW
54,000
-400 (-0.74%)
At close: Dec 5, 2025
11.46%
Market Cap 4.23T
Revenue (ttm) 624.03B
Net Income (ttm) -5.90B
Shares Out 78.37M
EPS (ttm) -75.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 94,687
Average Volume 141,906
Open 54,000
Previous Close 54,400
Day's Range 53,400 - 54,700
52-Week Range 35,800 - 61,300
Beta 1.15
RSI 53.72
Earnings Date Jan 29, 2026

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 917
Stock Exchange Korea Stock Exchange
Ticker Symbol 302440
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.